Paweł Burchardt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paweł Burchardt has a total of 196 co-authors. Here are the top co-authors by number of shared publications:
- Jan Budzianowski
Department of Interventional Cardiology and Cardiac Surgery, University of Zielona Gora, Collegium Medicum, Zielona Gora, Poland
9 shared publications - Jarosław Hiczkiewicz
University of Zielona Gora, Collegium Medicum, Department of Interventional Cardiology and Cardiac Surgery, Zielona Gora, Poland; Nowa Sol Multidisciplinar y Hospital, Nowa Sol, P oland
6 shared publications - Janusz Rzeźniczak
Department of Cardiology, J. Strus Hospital, 61-285 Poznań, Poland
5 shared publications - Marta Karaźniewicz-Łada
Department of Physical Pharmacy & Pharmacokinetics, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland
5 shared publications - Dominika Kasprzak
Department of Cardiology, J. Strus Hospital, Poznan, Poland
4 shared publications Henryk Wysocki
Division of Cardiology-Intensive Therapy, Poznan University of Medical Sciences, Poland
4 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (11) , 1705
Evaluation of Clinical and Genetic Determinants of Rivaroxaban Pharmacokinetics and Coagulation Parameters in Patients with Cardiovascular Diseases: An Exploratory Observational Study
Purpose: Interindividual variability in rivaroxaban exposure remains incompletely understood and may contribute to differences in treatment outcomes. This study aimed to investigate associations between polymorphisms in CYP3A4 (rs2242480), CYP2J2 (rs890293), and ABCB1 (rs1045642, rs2032582) genes, clinical factors and rivaroxaban pharmacokinetics. Methods: The study included 66 patients receiving 20 mg of rivaroxaban once daily. Rivaroxaban concentrations in plasma and dried blood spots were determined using a validated UPLC-MS/MS method. Genotyping was performed using PCR-RFLP. Associations between pharmacokinetic parameters, genetic variants and anthropometric characteristics, concomitant medications, comorbidities, and coagulation parameters were assessed using appropriate statistical analyses. Results: Carriers of the ABCB1 rs2032582 G allele exhibited lower rivaroxaban exposure, as reflected by reduced AUC0–12h values compared with non-carriers (1817.43 ± 703.70 vs. 2442.96 ± 691.13 ng·h/mL, nominal p = 0.0369). Concomitant use of eplerenone was associated with increased rivaroxaban exposure. Body mass composition and impaired renal function were associated with rivaroxaban concentrations. In addition, associations between CYP3A4 rs2242480 genotype and several body size descriptors, including body weight or lean body mass, and selected coagulation parameters were observed in exploratory analyses. However, most nominal associations did not remain statistically significant after correction for multiple comparisons. After Benjamini–Hochberg correction, only impaired renal function, drug interactions and biological sex remained statistically significant factors, impacting rivaroxaban’s pharmacokinetics and anticoagulant parameters. Conclusions: Several genetic and clinical factors showed nominal association with rivaroxaban pharmacokinetics and coagulation parameters in this study. These findings should be interpreted as exploratory given the limited sample size and the number of statistical comparisons. Further studies in larger cohorts are needed to clarify the clinical relevance of genetic and clinical determinants of rivaroxaban exposure.
- 29 October 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (11) , 1705
Open AccessEvaluation of Clinical and Genetic Determinants of Rivaroxaban Pharmacokinetics and Coagulation Parameters in Patients with Cardiovascular Diseases: An Exploratory Observational Study
Purpose: Interindividual variability in rivaroxaban exposure remains incompletely understood and may contribute to differences in treatment outcomes. This study aimed to investigate associations between polymorphisms in CYP3A4 (rs2242480), CYP2J2 (rs890293), and ABCB1 (rs1045642, rs2032582) genes, clinical factors and rivaroxaban pharmacokinetics. Methods: The study included 66 patients receiving 20 mg of rivaroxaban once daily. Rivaroxaban concentrations in plasma and dried blood spots were determined using a validated UPLC-MS/MS method. Genotyping was performed using PCR-RFLP. Associations between pharmacokinetic parameters, genetic variants and anthropometric characteristics, concomitant medications, comorbidities, and coagulation parameters were assessed using appropriate statistical analyses. Results: Carriers of the ABCB1 rs2032582 G allele exhibited lower rivaroxaban exposure, as reflected by reduced AUC0–12h values compared with non-carriers (1817.43 ± 703.70 vs. 2442.96 ± 691.13 ng·h/mL, nominal p = 0.0369). Concomitant use of eplerenone was associated with increased rivaroxaban exposure. Body mass composition and impaired renal function were associated with rivaroxaban concentrations. In addition, associations between CYP3A4 rs2242480 genotype and several body size descriptors, including body weight or lean body mass, and selected coagulation parameters were observed in exploratory analyses. However, most nominal associations did not remain statistically significant after correction for multiple comparisons. After Benjamini–Hochberg correction, only impaired renal function, drug interactions and biological sex remained statistically significant factors, impacting rivaroxaban’s pharmacokinetics and anticoagulant parameters. Conclusions: Several genetic and clinical factors showed nominal association with rivaroxaban pharmacokinetics and coagulation parameters in this study. These findings should be interpreted as exploratory given the limited sample size and the number of statistical comparisons. Further studies in larger cohorts are needed to clarify the clinical relevance of genetic and clinical determinants of rivaroxaban exposure.
- Open Access
- 5 February 2026
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 33, e00226057
Machine learning models of inflammatory markers used in the prediction of early and late atrial fibrillation recurrence in overweight and obese patients after catheter ablation
Background: Inflammation is associated with atrial fibrillation (AF) recurrence after catheter ablation. This study aimed to create machine learning models of inflammatory biomarkers and clinical parameters to predict early recurrence of atrial fibrillation (ERAF) and late recurrence of atrial fibrillation (LRAF) after catheter ablation. Methods: The study included 114 patients with abnormal body weight, defined as body mass index (BMI) > 25 kg/m², and paroxysmal, persistent, or long-standing persistent AF. Blood samples were collected at baseline and 24 hours after ablation. Almost 120 clinical and laboratory parameters were selected to develop machine learning models of ERAF and LRAF. Shapley additive explanations (SHAP) were derived to explain the obtained predictions. The models were trained and tuned for hyperparameters by five-fold cross-validation and subsequently evaluated on independent test sets using stratified sampling. Results: ERAF was observed in 20.3% of patients. LRAF was diagnosed in 26.3% of patients. The ERAF model with 5 variables — monocyte count, platelet-to-lymphocyte ratio (PLR), fibrinogen, and parameters measured before ablation, such as glomerular filtration rate (GFR) and left atrial volume — performed well in the studied cohort (mean AUC, 0.70 ± 0.06). The LRAF model with parameters such as neutrophil-to-lymphocyte ratio (NLR), soluble vascular cell adhesion molecule-1 (sVCAM-1), troponin, monocyte-to-HDL-C ratio (MHR), adiponectin, and ERAF also showed valuable performance (mean AUC, 0.77 ± 0.11). Conclusions: The machine learning model based on inflammatory biomarkers is a valuable tool for predicting ERAF. The combination of ERAF and inflammatory biomarkers significantly improves LRAF prediction. Keywords: biomarkers catheter ablation machine learning obesity
- 5 February 2026
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 33, e00226057
Open AccessMachine learning models of inflammatory markers used in the prediction of early and late atrial fibrillation recurrence in overweight and obese patients after catheter ablation
Background: Inflammation is associated with atrial fibrillation (AF) recurrence after catheter ablation. This study aimed to create machine learning models of inflammatory biomarkers and clinical parameters to predict early recurrence of atrial fibrillation (ERAF) and late recurrence of atrial fibrillation (LRAF) after catheter ablation. Methods: The study included 114 patients with abnormal body weight, defined as body mass index (BMI) > 25 kg/m², and paroxysmal, persistent, or long-standing persistent AF. Blood samples were collected at baseline and 24 hours after ablation. Almost 120 clinical and laboratory parameters were selected to develop machine learning models of ERAF and LRAF. Shapley additive explanations (SHAP) were derived to explain the obtained predictions. The models were trained and tuned for hyperparameters by five-fold cross-validation and subsequently evaluated on independent test sets using stratified sampling. Results: ERAF was observed in 20.3% of patients. LRAF was diagnosed in 26.3% of patients. The ERAF model with 5 variables — monocyte count, platelet-to-lymphocyte ratio (PLR), fibrinogen, and parameters measured before ablation, such as glomerular filtration rate (GFR) and left atrial volume — performed well in the studied cohort (mean AUC, 0.70 ± 0.06). The LRAF model with parameters such as neutrophil-to-lymphocyte ratio (NLR), soluble vascular cell adhesion molecule-1 (sVCAM-1), troponin, monocyte-to-HDL-C ratio (MHR), adiponectin, and ERAF also showed valuable performance (mean AUC, 0.77 ± 0.11). Conclusions: The machine learning model based on inflammatory biomarkers is a valuable tool for predicting ERAF. The combination of ERAF and inflammatory biomarkers significantly improves LRAF prediction. Keywords: biomarkers catheter ablation machine learning obesity
- Open Access
- 23 August 2025
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 21 (6) , 2258-2266
Updated Focused Review of Hematological, Inflammatory, and Lipid Biomarkers in Acute Coronary Syndrome
At present hematological indices and biomarkers of inflammation that may be associated with atherosclerosis and the prediction of acute coronary syndromes (ACS) attract a lot of academic attention. This update focused review aims to provide an overview of selected ACS biomarkers: white blood cells, neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, Systemic Inflammatory Index (SII), Systemic Inflammatory Response Index (SIRI) and Lipoprotein (a). Novel inflammatory-lipid biomarkers such as hsCRP to high density lipoprotein cholesterol (HDL-C) ratio, Neutrophils to HDL-C ratio, and Monocyte to HDL-C ratio may improve ACS diagnosis, risk stratification, clinical prognosis and optimal management. These indices are inexpensive and easily obtained in daily clinical practice. Artificial intelligence and genetic analysis may improve their diagnostic performance and guide clinical management. The recent data also emphasize that these indices may be a promising clinical tool for assessing ACS patients and monitoring the effectiveness of emerging anti-inflammatory strategies.
- 23 August 2025
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 21 (6) , 2258-2266
Open AccessUpdated Focused Review of Hematological, Inflammatory, and Lipid Biomarkers in Acute Coronary Syndrome
At present hematological indices and biomarkers of inflammation that may be associated with atherosclerosis and the prediction of acute coronary syndromes (ACS) attract a lot of academic attention. This update focused review aims to provide an overview of selected ACS biomarkers: white blood cells, neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, Systemic Inflammatory Index (SII), Systemic Inflammatory Response Index (SIRI) and Lipoprotein (a). Novel inflammatory-lipid biomarkers such as hsCRP to high density lipoprotein cholesterol (HDL-C) ratio, Neutrophils to HDL-C ratio, and Monocyte to HDL-C ratio may improve ACS diagnosis, risk stratification, clinical prognosis and optimal management. These indices are inexpensive and easily obtained in daily clinical practice. Artificial intelligence and genetic analysis may improve their diagnostic performance and guide clinical management. The recent data also emphasize that these indices may be a promising clinical tool for assessing ACS patients and monitoring the effectiveness of emerging anti-inflammatory strategies.
- Open Access
Selected Psychosocial Factors, Nutritional Behavior, and the Analysis of Concentrations of Selected Vitamins in Patients with Cardiovascular Diseases
Cardiovascular diseases (CVD) are the leading cause of death worldwide, influenced by the interaction of factors, including age, sex, genetic conditions, overweight/obesity, hypertension, an abnormal lipid profile, vitamin deficiencies, diabetes, and psychological factors. This study aimed to assess the relationships between psychosocial and nutritional factors in a group of 61 patients with CVD (i.e., atherosclerosis, hypertension, ischemic heart disease, and myocardial infarction) and their possible impact on the course of the disease. The plasma concentrations of vitamins A, E, D, and β-carotene were determined using validated HPLC-MS/MS, while the lipid profile was analyzed enzymatically. Psychosocial factors and nutritional behaviors were assessed using author-designed questionnaires. Over 50% of patients had 25-OH-D3 and retinol deficiencies, while >85% of patients exhibited significant deficiencies in α-tocopherol and β-carotene. The lipid profile showed no specific relationship with any particular CVD. Dietary behavior minimally impacted biochemical parameters except for higher β-carotene concentrations in the group with higher fruit and vegetable intake. The negative impact of the CVD on selected parameters of quality of life was noticed. To increase the effectiveness of the prevention and treatment of CVD, the need for interdisciplinary cooperation observed between doctors, psychologists, and specialists in human nutrition seems to be justified.
Open AccessSelected Psychosocial Factors, Nutritional Behavior, and the Analysis of Concentrations of Selected Vitamins in Patients with Cardiovascular Diseases
Cardiovascular diseases (CVD) are the leading cause of death worldwide, influenced by the interaction of factors, including age, sex, genetic conditions, overweight/obesity, hypertension, an abnormal lipid profile, vitamin deficiencies, diabetes, and psychological factors. This study aimed to assess the relationships between psychosocial and nutritional factors in a group of 61 patients with CVD (i.e., atherosclerosis, hypertension, ischemic heart disease, and myocardial infarction) and their possible impact on the course of the disease. The plasma concentrations of vitamins A, E, D, and β-carotene were determined using validated HPLC-MS/MS, while the lipid profile was analyzed enzymatically. Psychosocial factors and nutritional behaviors were assessed using author-designed questionnaires. Over 50% of patients had 25-OH-D3 and retinol deficiencies, while >85% of patients exhibited significant deficiencies in α-tocopherol and β-carotene. The lipid profile showed no specific relationship with any particular CVD. Dietary behavior minimally impacted biochemical parameters except for higher β-carotene concentrations in the group with higher fruit and vegetable intake. The negative impact of the CVD on selected parameters of quality of life was noticed. To increase the effectiveness of the prevention and treatment of CVD, the need for interdisciplinary cooperation observed between doctors, psychologists, and specialists in human nutrition seems to be justified.
- 10 June 2024
- Published by Taylor & Francis in Future Cardiology
- Vol. 20 (7-8) , 377-387
The influence of P2Y 12 gene polymorphisms on clopidogrel therapy in patients after percutaneous coronary intervention
Aim: We aimed to define the influence of P2Y12 polymorphisms (rs6801273, rs2046934, and rs6809699), diabetes, hypertension, obesity, hypercholesterolemia, statins intake, and smoking habit on clopidogrel therapy in patients undergoing percutaneous coronary intervention. Materials & methods: We used PCR-RFLP and PCR-ASO for P2Y(12) genotype analysis. The effectiveness of the therapy was measured with the VerifyNow method and defined in platelet reactivity units. Results: Studied polymorphisms had no statistically significant influence on PRU before (PRU0) and 6 months (PRU6) after the procedure. H1/H1 diabetic carriers had significantly higher PRU6 values than patients without diabetes. Obese H1/H2 subjects had significantly lower PRU6 values than H1/H2 non-obese carriers. Conclusion: We found that obesity and diabetes may influence the long-term outcome of antiplatelet therapy.
- 10 June 2024
- Published by Taylor & Francis in Future Cardiology
- Vol. 20 (7-8) , 377-387
The influence of P2Y 12 gene polymorphisms on clopidogrel therapy in patients after percutaneous coronary intervention
Aim: We aimed to define the influence of P2Y12 polymorphisms (rs6801273, rs2046934, and rs6809699), diabetes, hypertension, obesity, hypercholesterolemia, statins intake, and smoking habit on clopidogrel therapy in patients undergoing percutaneous coronary intervention. Materials & methods: We used PCR-RFLP and PCR-ASO for P2Y(12) genotype analysis. The effectiveness of the therapy was measured with the VerifyNow method and defined in platelet reactivity units. Results: Studied polymorphisms had no statistically significant influence on PRU before (PRU0) and 6 months (PRU6) after the procedure. H1/H1 diabetic carriers had significantly higher PRU6 values than patients without diabetes. Obese H1/H2 subjects had significantly lower PRU6 values than H1/H2 non-obese carriers. Conclusion: We found that obesity and diabetes may influence the long-term outcome of antiplatelet therapy.
- Open Access
- 1 June 2024
- Published by AME Publishing Company in Cardiovascular Diagnosis and Therapy
- Vol. 14 (3) , 314-317
Myocardial involvement in post-COVID-19 condition: a note from the surgical approach
Myocardial involvement in post-COVID-19 condition: a note from the surgical approach
- 1 June 2024
- Published by AME Publishing Company in Cardiovascular Diagnosis and Therapy
- Vol. 14 (3) , 314-317
Open AccessMyocardial involvement in post-COVID-19 condition: a note from the surgical approach
Myocardial involvement in post-COVID-19 condition: a note from the surgical approach
- 17 February 2024
- Published by Taylor & Francis in Future Cardiology
- Vol. 20 (3) , 123-135
Associations between vitamin D status, VDR gene polymorphisms and echocardiographic markers in Polish patients with cardiovascular disease
Aim: This work was designed to investigate the associations between vitamin D metabolites, VDR gene polymorphisms and echocardiographic markers in a population of patients with cardiovascular disea... Plain language summary Vitamin D levels in the body and variations in the vitamin D receptor gene are linked to specific heart-related markers in Polish patients with heart conditions. What is this... Tweetable abstract A potential link exists between VDR gene polymorphisms and cardiovascular function.
- 17 February 2024
- Published by Taylor & Francis in Future Cardiology
- Vol. 20 (3) , 123-135
Associations between vitamin D status, VDR gene polymorphisms and echocardiographic markers in Polish patients with cardiovascular disease
Aim: This work was designed to investigate the associations between vitamin D metabolites, VDR gene polymorphisms and echocardiographic markers in a population of patients with cardiovascular disea... Plain language summary Vitamin D levels in the body and variations in the vitamin D receptor gene are linked to specific heart-related markers in Polish patients with heart conditions. What is this... Tweetable abstract A potential link exists between VDR gene polymorphisms and cardiovascular function.
- Open Access
- 15 February 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (4) , 1096
Predictors of Revascularization in Patients with Unstable Angina
Background: The factors that determine the necessity of coronary artery revascularization in patients with unstable angina (UA) have been supported by limited data. Therefore, this study aimed to identify the predictors of revascularization in patients with UA. Methods: The study included the recorded data of 3668 patients with UA who underwent cardiac catheterization (age 66 ± 9.2, men 70%); 2615 of them (71%) underwent revascularization (percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass graft (CABG), or hybrid revascularization. The remaining 1053 patients (29%) had no significant coronary stenosis and were regarded as controls. Multivariable logistic regression analysis was performed to separate the predictors of revascularization. Results: It was found that severe angina (OR 2.7, 95%CI 1.9–3.7), male gender (OR 1.4, 95%CI 1.1–1.7), and hyperlipidemia were the predictors of revascularization. It was also noted that intraventricular conduction disorders including left and right bundle branch blocks and a history of previous revascularization and myocardial infarction were associated with lower odds of revascularization. Conclusion: Overall, however, the predictive value of the studied factors proved to be poor and may still point to the multifactorial nature of significant coronary artery stenosis and the need for revascularization in patients with UA.
- 15 February 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (4) , 1096
Open AccessPredictors of Revascularization in Patients with Unstable Angina
Background: The factors that determine the necessity of coronary artery revascularization in patients with unstable angina (UA) have been supported by limited data. Therefore, this study aimed to identify the predictors of revascularization in patients with UA. Methods: The study included the recorded data of 3668 patients with UA who underwent cardiac catheterization (age 66 ± 9.2, men 70%); 2615 of them (71%) underwent revascularization (percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass graft (CABG), or hybrid revascularization. The remaining 1053 patients (29%) had no significant coronary stenosis and were regarded as controls. Multivariable logistic regression analysis was performed to separate the predictors of revascularization. Results: It was found that severe angina (OR 2.7, 95%CI 1.9–3.7), male gender (OR 1.4, 95%CI 1.1–1.7), and hyperlipidemia were the predictors of revascularization. It was also noted that intraventricular conduction disorders including left and right bundle branch blocks and a history of previous revascularization and myocardial infarction were associated with lower odds of revascularization. Conclusion: Overall, however, the predictive value of the studied factors proved to be poor and may still point to the multifactorial nature of significant coronary artery stenosis and the need for revascularization in patients with UA.
- Top Cited Papers
- 31 January 2024
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 20 (1) , 8-27
Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels
Lipoprotein(a) [Lp(a)] is made up of a low-density lipoprotein (LDL) particle and a specific apolipoprotein(a). The blood concentration of Lp(a) is approximately 90% genetically determined, and the main genetic factor determining Lp(a) levels is the size of the apo(a) isoform, which is determined by the number of KIV2 domain repeats. The size of the apo(a) isoform is inversely proportional to the blood concentration of Lp(a). Lp(a) is a strong and independent cardiovascular risk factor. Elevated Lp(a) levels ≥ 50 mg/dl (≥ 125 nmol/l) are estimated to occur in more than 1.5 billion people worldwide. However, determination of Lp(a) levels is performed far too rarely, including Poland, where, in fact, it is only since the 2021 guidelines of the Polish Lipid Association (PoLA) and five other scientific societies that Lp(a) measurements have begun to be performed. Determination of Lp(a) concentrations is not easy due to, among other things, the different sizes of the apo(a) isoforms; however, the currently available certified tests make it possible to distinguish between people with low and high cardiovascular risk with a high degree of precision. In 2022, the first guidelines for the management of patients with elevated lipoprotein(a) levels were published by the European Atherosclerosis Society (EAS) and the American Heart Association (AHA). The first Polish guidelines are the result of the work of experts from the two scientific societies and their aim is to provide clear, practical recommendations for the determination and management of elevated Lp(a) levels.
- 31 January 2024
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 20 (1) , 8-27
Top Cited PapersRecommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels
Lipoprotein(a) [Lp(a)] is made up of a low-density lipoprotein (LDL) particle and a specific apolipoprotein(a). The blood concentration of Lp(a) is approximately 90% genetically determined, and the main genetic factor determining Lp(a) levels is the size of the apo(a) isoform, which is determined by the number of KIV2 domain repeats. The size of the apo(a) isoform is inversely proportional to the blood concentration of Lp(a). Lp(a) is a strong and independent cardiovascular risk factor. Elevated Lp(a) levels ≥ 50 mg/dl (≥ 125 nmol/l) are estimated to occur in more than 1.5 billion people worldwide. However, determination of Lp(a) levels is performed far too rarely, including Poland, where, in fact, it is only since the 2021 guidelines of the Polish Lipid Association (PoLA) and five other scientific societies that Lp(a) measurements have begun to be performed. Determination of Lp(a) concentrations is not easy due to, among other things, the different sizes of the apo(a) isoforms; however, the currently available certified tests make it possible to distinguish between people with low and high cardiovascular risk with a high degree of precision. In 2022, the first guidelines for the management of patients with elevated lipoprotein(a) levels were published by the European Atherosclerosis Society (EAS) and the American Heart Association (AHA). The first Polish guidelines are the result of the work of experts from the two scientific societies and their aim is to provide clear, practical recommendations for the determination and management of elevated Lp(a) levels.
- Open Access
- 27 July 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (15) , 4954
Cognitive Impairment in Cardiovascular Patients after Myocardial Infarction: Prospective Clinical Study
(1) Background: Assessment of cognitive function is not routine in cardiac patients, and knowledge on the subject remains limited. The aim of this study was to assess post-myocardial infarction (MI) cognitive functioning in order to determine the frequency of cognitive impairment (CI) and to identify factors that may influence it. (2) Methods: A prospective study included 468 patients hospitalized for MI. Participants were assessed twice: during the first hospitalization and 6 months later. The Mini-Mental State Examination was used to assess the occurrence of CI. (3) Results: Cognitive dysfunction based on the MMSE was found in 37% (N-174) of patients during the first hospitalization. After 6 months, the prevalence of deficits decreased significantly to 25% (N-91) (p < 0.001). Patients with CI significantly differed from those without peri-infarction deficits in the GFR, BNP, ejection fraction and SYNTAX score, while after 6 months, significant differences were observed in LDL and HCT levels. There was a high prevalence of non-cognitive mental disorders among post-MI patients. (4) Conclusions: There is a high prevalence of CI and other non-cognitive mental disorders, such as depression, sleep disorders and a tendency to aggression, among post-MI patients. The analysis of the collected material indicates a significant impact of worse cardiac function expressed as EF and BNP, greater severity of coronary atherosclerosis expressed by SYNTAX results, and red blood cell parameters and LDL levels on the occurrence of CI in the post-MI patient population.
- 27 July 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (15) , 4954
Open AccessCognitive Impairment in Cardiovascular Patients after Myocardial Infarction: Prospective Clinical Study
(1) Background: Assessment of cognitive function is not routine in cardiac patients, and knowledge on the subject remains limited. The aim of this study was to assess post-myocardial infarction (MI) cognitive functioning in order to determine the frequency of cognitive impairment (CI) and to identify factors that may influence it. (2) Methods: A prospective study included 468 patients hospitalized for MI. Participants were assessed twice: during the first hospitalization and 6 months later. The Mini-Mental State Examination was used to assess the occurrence of CI. (3) Results: Cognitive dysfunction based on the MMSE was found in 37% (N-174) of patients during the first hospitalization. After 6 months, the prevalence of deficits decreased significantly to 25% (N-91) (p < 0.001). Patients with CI significantly differed from those without peri-infarction deficits in the GFR, BNP, ejection fraction and SYNTAX score, while after 6 months, significant differences were observed in LDL and HCT levels. There was a high prevalence of non-cognitive mental disorders among post-MI patients. (4) Conclusions: There is a high prevalence of CI and other non-cognitive mental disorders, such as depression, sleep disorders and a tendency to aggression, among post-MI patients. The analysis of the collected material indicates a significant impact of worse cardiac function expressed as EF and BNP, greater severity of coronary atherosclerosis expressed by SYNTAX results, and red blood cell parameters and LDL levels on the occurrence of CI in the post-MI patient population.